Research

Hormonal

Tirzepatide, a dual GIP/GLP-1 receptor agonist, achieves greater glycemic control and weight loss compared to isolated GLP-1 receptor agonism.

For individuals with Type 2 Diabetes or obesity who need more than standard GLP-1 medications, Tirzepatide is a newer option that targets two hormone receptors (GIP and GLP-1). Clinical trials show it can lower blood sugar by more than 2% and achieve weight loss exceeding 15%, which is greater than what is typically seen with GLP-1-only drugs.

GoodSupportsHIGH confidence
Tirzepatide has emerged as a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA, with more striking effects on glycemic control and weight reduction than those achieved by isolated GLP-1R agonism alone. This consists of lowering glycated hemoglobin levels by more than 2% and weight loss exceeding 15% from baseline.
James P. Psaltis et al. · Medicinal Research Reviews · 2024

Why this rating

Supported by Phase 3 clinical trials (SURPASS, SURMOUNT) showing significant reductions in HbA1c and weight loss, though long-term cardiovascular outcome data is still emerging compared to GLP-1 RAs.

Source

Incretin‐based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future

James P. Psaltis et al. · Medicinal Research Reviews · 2024

DOI 10.1002/med.22070

narrative_reviewCited 34×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →